Drug Developement
Drug Development Use Cases
Venetoclax Combinations
Next Generation
Patient stratification and pharmacodynamic readouts for venetoclax plus azacitidine or other combination regimens in AML and MM, identifying patients most likely to achieve durable responses.
- Baseline priming profiles predict clinical benefit
- On-treatment shifts quantify drug mechanism
- Resistance monitoring guides salvage therapy
Rational design of doublets and triplets pairing BH3 mimetics with metabolic modulators, stress-kinase inhibitors, and cell-cycle agents by quantifying how diverse pathways converge on mitochondrial apoptosis.
- MCL-1 inhibitor patient selection algorithms
- Novel combination synergy prediction
- Biomarker-driven clinical trial enrichment
Dynamic shifts in BCL-2 Family PPIs Direct Combination Treatments
The PRIMABs measurements of drug induced shifts in priming can provide utility in predicting patient response.
Drug displacement of Bim changes cancer dependency
The PRIMABs measurements of drug induced shifts in priming can provide utility in predicting patient response.
Here the displacement of BIM from BCL-2 and corresponding binding to MCL-1 is illustrated. This shift is seen to be a cause of venetoclax resistance. Detecting this shift is an indicator of impending resistance to tratment
Here the displacement of BIM from BCL-2 and corresponding binding to MCL-1 is illustrated. This shift is seen to be a cause of venetoclax resistance. Detection of this shift instructs treatment that impacts MCL-1 Bim Complex
Dynamic PRIMABS™ Readouts Detect Priming Shifts
The data shows that PRIMABS detect such a shift in priming status following BH3-mimetic treatment (priming changes from Bcl-xL to MCL-1) that correlates to specific drug sensitivity..
Cell line samples were measured with PRIMABS staining and flow detection before and after treatment .